Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001562180-20-006582)

Filing Details

Accession Number:
0001562180-20-006582
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-06 16:47:37
Reporting Period:
2020-11-04
Accepted Time:
2020-11-06 16:47:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
842023 Bio-Techne Corp TECH Biological Products, (No Disgnostic Substances) (2836) 411427402
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1603594 James Hippel 614 Mckinley Place N.e.
Minneapolis MN 55413		 Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-04 7,100 $108.49 16,237 No 4 M Direct
Common Stock Disposition 2020-11-04 1,555 $272.71 14,682 No 4 S Direct
Common Stock Disposition 2020-11-04 2,745 $273.65 11,937 No 4 S Direct
Common Stock Disposition 2020-11-04 1,600 $274.53 10,337 No 4 S Direct
Common Stock Disposition 2020-11-04 1,200 $275.79 9,137 No 4 S Direct
Common Stock Acquisiton 2020-11-05 8,809 $108.49 17,946 No 4 M Direct
Common Stock Disposition 2020-11-05 398 $280.28 17,548 No 4 S Direct
Common Stock Disposition 2020-11-05 203 $281.27 17,345 No 4 S Direct
Common Stock Disposition 2020-11-05 1,674 $282.52 15,671 No 4 S Direct
Common Stock Disposition 2020-11-05 325 $283.64 15,346 No 4 S Direct
Common Stock Disposition 2020-11-05 1,630 $285.12 13,716 No 4 S Direct
Common Stock Disposition 2020-11-05 121 $287.15 13,595 No 4 S Direct
Common Stock Disposition 2020-11-05 3,249 $287.98 10,346 No 4 S Direct
Common Stock Disposition 2020-11-05 359 $289.39 9,987 No 4 S Direct
Common Stock Disposition 2020-11-05 750 $291.06 9,237 No 4 S Direct
Common Stock Disposition 2020-11-05 100 $293.66 9,137 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-11-04 7,100 $0.00 7,100 $108.49
Common Stock Stock Option (Right to Buy) Disposition 2020-10-05 8,809 $0.00 8,809 $108.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,100 2022-08-07 No 4 M Direct
0 2022-08-07 No 4 M Direct
Reported Derivative Holdings
Show Other Fields >>
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (Right to Buy) $106.59 2023-08-18 30,400 30,400 Direct
Common Stock Stock Options (Right to Buy) $106.59 2023-08-18 40,533 40,533 Direct
Common Stock Stock Options (Right to buy) $125.05 2024-08-09 24,460 24,460 Direct
Common Stock Stock Options (Right to Buy) $125.05 2024-08-09 32,613 32,613 Direct
Common Stock Restricted Stock Units $0.00 3,383 3,383 Direct
Common Stock Stock Options (Right to buy) $177.32 2025-08-08 18,066 18,066 Direct
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 24,089 24,089 Direct
Common Stock Restricted Stock Units $0.00 3,938 3,938 Direct
Common Stock Stock Option (Right to Buy) $190.41 2026-08-07 19,936 19,936 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 26,581 26,581 Direct
Common Stock Restricted Stock Unit $0.00 3,219 3,219 Direct
Common Stock Stock Option (Right to Buy) $267.87 2027-08-05 14,360 14,360 Direct
Common Stock Stock Options (Right to Buy) $267.87 2027-08-05 19,147 19,147 Direct
Common Stock Stock Options (Right to buy) $267.87 2027-08-05 8,325 8,325 Direct
Common Stock Stock Options (Right to buy) $267.87 2027-08-05 8,325 8,325 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2023-08-18 30,400 30,400 Direct
2023-08-18 40,533 40,533 Direct
2024-08-09 24,460 24,460 Direct
2024-08-09 32,613 32,613 Direct
3,383 3,383 Direct
2025-08-08 18,066 18,066 Direct
2025-08-08 24,089 24,089 Direct
3,938 3,938 Direct
2026-08-07 19,936 19,936 Direct
2026-08-07 26,581 26,581 Direct
3,219 3,219 Direct
2027-08-05 14,360 14,360 Direct
2027-08-05 19,147 19,147 Direct
2027-08-05 8,325 8,325 Direct
2027-08-05 8,325 8,325 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.21 to $273.20, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.23 to $274.19, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.24 to $275.045, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.38 to $276.30, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.84 to $280.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.00 to $281.55, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.00 to $282.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.57 to $284.48, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $285.00 to $285.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.67 to $287.25, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $287.68 to $288.46, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $289.00 to $289.58, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $290.66 to $291.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.66 to $293.66, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  15. Fully exercisable.
  16. Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021.
  17. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
  18. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  19. Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.
  20. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  21. Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
  22. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator.
  23. Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.
  24. Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
  25. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
Insider Monkey Quarterly Strategy
+334.6% Insider Monkey Quarterly Strategy
+149.4% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF
300%
200%
100%
Subscribe Now

Returns since its inception in May 2014 (through November 14th, 2024)